Loading...

CNTN CANTON STRATEGIC HOLDINGS INC Expansion Plans 8-K Filing

CNTN

CNTN

CANTON STRATEGIC HOLDINGS INC

(CNTN)

2024 8-K

Annual Results Released

Sales Agreement Update

Director Appointment

Name Change Update

Leadership Changes

Special Meeting Results

New Validator Role

Stock Offering Update

Pricing Announcement

Board Compliance Update

Management Change

Management Change

ATM Offering Initiated

Financial Update

Funding Agreement Update

Securities Offering Update

Stockholder Approvals

Warrant Amendment

Salary Increase

Nasdaq Compliance Confirmed

Stockholder Equity Confirma...

Securities Offering

Securities Offering

Equity Offerings

Equity Offerings

Equity Offerings

Board Appointment

Management Changes

Private Placement

Acquisition Intent

Patent License Agreement

Securities Purchase Agreement

Compliance with Nasdaq List...

Agreement for Stock Sale

Amendment to Certificate of...

Annual Meeting of Stockholders

Amendment to Bylaws

Compliance Extension

Public Offering and Exceedi...

Public Offering

Regulation FD Disclosure

Phase 1 Data Announcement

Amendment to Certificate of...

Delisting Notice

Patent License Agreement wi...

Annual Meeting Results

Appointment of Accountant

Accountant Resignation

Delisting Notice

Restatement of Financial St...

Appointment of Directors

Public Offering

Compliance with Nasdaq's mi...

Regulation FD Disclosure

External Links:

Tharimmune, Inc. has entered into a Patent License Agreement with Intract Pharma for the exclusive rights to develop and commercialize an oral anti-TNF monoclonal antibody, infliximab, receiving an upfront payment and potential future royalties based on sales.

AI Assistant

CANTON STRATEGIC HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.